News Releases

May 11, 2022
Biodesix Announces First Quarter 2022 Results and Highlights
First quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021; Continued to strengthen financial position through an additional $27.4 million in debt and equity funding during second quarter 2022; Conference Call and Webcast Today at 8:00 a.m.
Apr 27, 2022
Biodesix to Report First Quarter 2022 Financial Results on May 11, 2022
BOULDER, Colo. --(BUSINESS WIRE)--Apr. 27, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the first quarter ended March 31, 2022 before the open of trading on
Mar 14, 2022
Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods, respectively Full-Scale Launch of GeneStrat NGS™ Test in January 2022 Conference Call and Webcast Today at 8:30 a.m. ET BOULDER, Colo.
Mar 01, 2022
Biodesix to Present at Cowen’s 42nd Annual Healthcare Conference
BOULDER, Colo. --(BUSINESS WIRE)--Mar. 1, 2022-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present at Cowen’s 42nd Annual Healthcare Conference being held
Displaying 1 - 10 of 16